A recent study has found that antibodies which target PD-L1 are more effective than PD-1 inhibitors at blocking PD-1/PD-L1 signaling (see link below). PD-1 has been […]

We would like to celebrate Amgen’s partnership with the Lazarex Cancer Foundation, an organization which is dedicated to creating equitable access to clinical trials for all […]

In honor of Lung Cancer Awareness Day (August 1st), we would like to call attention to assets currently in phase III for small cell lung cancer! […]

Eli Lilly announced that it is pulling the plug on LY3415244, the company’s only bispecific antibody currently in pipeline (see attached article). So which modalities is […]

Interesting article about BMS expanding Opdivo’s colorectal cancer indication. Which companies could be impacted by this expansion? Kognitic’s platform can show you which companies have new […]

The number of emerging transformative therapy clinical trials are on the rise for the past few years. The therapies target multiple tumors and it’s difficult to […]

Number of industry sponsored clinical trials in immunotherapy over the past two years. Classification of Immunotherapy and the tumors they are active in

Automation and new computer technologies are revolutionizing all industrial areas. Until a few years ago, developing a new product was extremely protracted not to mention highly […]